Empleo del cannabidiol (cbd) en la osteoartrosis canina

  1. Lara Herrera, Víctor 1
  2. Cárceles Rodríguez, Carlos 1
  1. 1 Departamento de Farmacología. Facultad de Veterinaria. Universidad de Murcia
Revue:
Anales de veterinaria de Murcia

ISSN: 0213-5434,  1989-1784

Année de publication: 2023

Número: 37

Type: Article

DOI: 10.6018/ANALESVET.560831 DIALNET GOOGLE SCHOLAR lock_openDIGITUM editor

D'autres publications dans: Anales de veterinaria de Murcia

Objectifs de Développement Durable

Résumé

The Cannabis sativa plant is made up of a wide variety of active ingredients, which are called cannabinoids. There are 3 different types of cannabinoids: endocannabinoids, phytocannabinoids or herbal cannabinoids and synthetic cannabinoids.   This study focuses on the development of CBD, as it is a product that produces minimal or no psychoactive effects and has no toxicity to animals.  The vast majority of animals have an endocannabinoid system. This system consists of endogenous agonists and their receptors. This endocannabinoid system is also physiologically involved in the regulation of analgesia, learning, locomotor activity, anxiety, appetite, gastrointestinal motility, immune control and cardiovascular function.   CBD acts on a multitude of receptors in the body, producing a wide range of therapeutic actions.  Osteoarthrosis is an autodegenerative joint disease for which pain is the main clinical sign. Currently, the pharmacological management of OA  may not produce adequate analgesia and may have undesirable effects.   The main objective of this study was to determine whether CBD could be an alternative in the treatment of OA or whether it could be used together in a multimodal treatment. To this end, five different articles were chosen.  The results of the studies showed that CBD significantly reduced the sensation of pain and improved quality of life. Secondary clinical signs were not observed when administering CBD, except from an increase in alkaline phosphatase which  could cause liver damage.   The conclusions that can be drawn from this study are that CBD is a product with great therapeutic potential, minimal effective dose and minimal adverse effects. It proves to be a very complete drug, which needs further studies to be used more widely and without risk.  

Références bibliographiques

  • Bloomfield, M. A. P., Hindocha, C., Green, S. F., Wall, M. B., Lees, R., Petrilli, K., Costello, H., Ogunbiyi, M. O., Bossong, M. G., & Freeman, T. P. (2019). The neuropsychopharmacology of cannabis: A review of human imaging studies. Pharmacology & Therapeutics, 195, 132–161. https://doi.org/10.1016/J.PHARMTHERA.2018.10.006
  • Boggs, D. L., Nguyen, J. D., Morgenson, D., Taffe, M. A., & Ranganathan, M. (2017). Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol. Neuropsychopharmacology 2018 43:1, 43(1), 142–154. https://doi.org/10.1038/npp.2017.209
  • Brioschi, F. A., di Cesare, F., Gioeni, D., Rabbogliatti, V., Ferrari, F., D’urso, E. S., Amari, M., & Ravasio, G. (2020). Oral transmucosal cannabidiol oil formulation as part of a multimodal analgesic regimen: Effects on pain relief and quality of life improvement in dogs affected by spontaneous osteoarthritis. Animals, 10(9), 1–14. https://doi.org/10.3390/ani10091505
  • de Briyne, N., Holmes, D., Sandler, I., Stiles, E., Szymanski, D., Moody, S., Neumann, S., & Anadón, A. (2021). Cannabis, Cannabidiol Oils and Tetrahydrocannabinol—What Do Veterinarians Need to Know? Animals 2021, Vol. 11, Page 892, 11(3), 892. https://doi.org/10.3390/ANI11030892
  • Deabold, K. A., Schwark, W. S., Wolf, L., & Wakshlag, J. J. (2019). Single-Dose Pharmacokinetics and Preliminary Safety Assessment with Use of CBD-Rich Hemp Nutraceutical in Healthy Dogs and Cats. Animals, 9(10). https://doi.org/10.3390/ani9100832
  • Dhital, S., Stokes, J. v., Park, N., Seo, K. S., & Kaplan, B. L. F. (2017). Cannabidiol (CBD) induces functional Tregs in response to low-level T cell activation. Cellular Immunology, 312, 25–34. https://doi.org/10.1016/j.cellimm.2016.11.006
  • D’Souza, D. C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y. te, Braley, G., Gueorguieva, R., & Krystal, J. H. (2004). The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis. Neuropsychopharmacology 2004 29:8, 29(8), 1558–1572. https://doi.org/10.1038/sj.npp.1300496
  • ElSohly, M. A., Gul, W., Wanas, A. S., & Radwan, M. M. (2014). Synthetic cannabinoids: Analysis and metabolites. Life Sciences, 97(1), 78–90. https://doi.org/10.1016/J.LFS.2013.12.212
  • Francesc Pla Juncá. (2022). Farmacología de la interacción del tetrahidrocannabinol y cannabidiol en voluntarios sanos. Departamento de farmacología, terapéutica y toxicología, universidad autónoma de Barcelona.
  • Gamble, L. J., Boesch, J. M., Frye, C. W., Schwark, W. S., Mann, S., Wolfe, L., Brown, H., Berthelsen, E. S., & Wakshlag, J. J. (2018). Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs. Frontiers in Veterinary Science, 5. https://doi.org/10.3389/fvets.2018.00165
  • Greb, A., & Puschner, B. (2018). Cannabinoid treats as adjunctive therapy for pets: gaps in our knowledge. Https://Doi.Org/10.1080/24734306.2018.1434470, 2(1), 10–14. https://doi.org/10.1080/24734306.2018.1434470
  • Gugliandolo, E., Licata, P., Peritore, A. F., Siracusa, R., D’amico, R., Cordaro, M., Fusco, R., Impellizzeri, D., di Paola, R., Cuzzocrea, S., Crupi, R., & Interlandi, C. D. (2021). Effect of cannabidiol (Cbd) on canine inflammatory response: An ex vivo study on lps stimulated whole blood. Veterinary Sciences, 8(9). https://doi.org/10.3390/vetsci8090185
  • Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., Mechoulam, R., & Pertwee, R. G. (2002). International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors. Pharmacological Reviews, 54(2), 161–202. https://doi.org/10.1124/PR.54.2.161
  • Kogan, L. R. (2020). The Use of Cannabidiol-Rich Hemp Oil Extract to Treat Canine Osteoarthritis-Related Pain: A Pilot Study The frequency and type of vehicular restraint of dogs within the UK, USA and Australia View project Emotional support animals View project. https://www.researchgate.net/publication/339698157
  • Landa, L., Sulcova, A., & Gbelec, P. (2016). The use of cannabinoids in animals and therapeutic implications for veterinary medicine: a review. Http://Agriculturejournals.Cz/Doi/10.17221/8762-VETMED.Html, 61(3), 111–122. https://doi.org/10.17221/8762-VETMED
  • Maida, V., & Daeninck, P. J. (2016). A User’s Guide to Cannabinoid Therapies in Oncology. Current Oncology 2016, Vol. 23, Pages 398-406, 23(6), 398–406. https://doi.org/10.3747/CO.23.3487
  • Morris, E. M., Kitts-Morgan, S. E., Spangler, D. M., Gebert, J., Vanzant, E. S., McLeod, K. R., & Harmon, D. L. (2021). Feeding Cannabidiol (CBD)-Containing Treats Did Not Affect Canine Daily Voluntary Activity. Frontiers in Veterinary Science, 8. https://doi.org/10.3389/fvets.2021.645667
  • Morrow, L., & Belshaw, Z. (2020). Does the addition of cannabidiol alongside current drug treatments reduce pain in dogs with osteoarthritis? In Veterinary Record (Vol. 186, Issue 15, pp. 493–494). British Veterinary Association. https://doi.org/10.1136/vr.m1594
  • Nichols, J. M., Kummari, E., Sherman, J., Yang, E. J., Dhital, S., Gilfeather, C., Yray, G., Morgan, T., & Kaplan, B. L. F. (2021). CBD Suppression of EAE Is Correlated with Early Inhibition of Splenic IFN-γ + CD8+ T Cells and Modest Inhibition of Neuroinflammation. Journal of Neuroimmune Pharmacology, 16(2), 346–362. https://doi.org/10.1007/s11481-020-09917-8
  • Papagianni, E. P., & Stevenson, C. W. (2019). Cannabinoid Regulation of Fear and Anxiety: an Update. Current Psychiatry Reports, 21(6), 1–10. https://doi.org/10.1007/S11920-019-1026-Z/METRICS
  • Pertwee, R. G. (2012). Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, 367(1607), 3353–3363. https://doi.org/10.1098/RSTB.2011.0381
  • Potschka, H., Bhatti, S. F. M., Tipold, A., & McGrath, S. (2022). Cannabidiol in canine epilepsy. Veterinary Journal. https://doi.org/10.1016/j.tvjl.2022.105913
  • Silver, R. J. (2019). The Endocannabinoid System of Animals. Animals 2019, Vol. 9, Page 686, 9(9), 686. https://doi.org/10.3390/ANI9090686
  • Taylor, L., Gidal, B., Blakey, G., Tayo, B., & Morrison, G. (2018). A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. CNS Drugs, 32(11), 1053–1067. https://doi.org/10.1007/S40263-018-0578-5/TABLES/9
  • Verrico, C. D., Wesson, S., Konduri, V., Hofferek, C. J., Vazquez-Perez, J., Blair, E., Dunner, K., Salimpour, P., Decker, W. K., & Halpert, M. M. (2020). A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain. Pain, 161(9), 2191–2202. https://doi.org/10.1097/j.pain.0000000000001896
  • Wallace, J. E., Kogan, L. R., Carr, E. C. J., & Hellyer, P. W. (2020). Motivations and expectations for using cannabis products to treat pain in humans and dogs: a mixed methods study. Journal of Cannabis Research 2020 2:1, 2(1), 1–12. https://doi.org/10.1186/S42238-020-00045-X
  • Yu, C. H. J., & Rupasinghe, H. P. V. (2021). Cannabidiol-based natural health products for companion animals: Recent advances in the management of anxiety, pain, and inflammation. In Research in Veterinary Science (Vol. 140, pp. 38–46). Elsevier B.V. https://doi.org/10.1016/j.rvsc.2021.08.001
  • Zou, S., & Kumar, U. (2018). Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. International Journal of Molecular Sciences, 19(3). https://doi.org/10.3390/IJMS19030833
La source de données: Dialnet